Valuation: Sanofi

Market Cap 91.4B 104B 85.02B 78B 147B 10,030B 149B 1,008B 394B 4,922B 391B 382B 17,037B P/E 2026 *
11.4x
P/E 2027 * 10.5x
Enterprise Value 101B 115B 94.14B 86.37B 162B 11,106B 165B 1,116B 437B 5,450B 432B 423B 18,865B EV / Sales 2026 *
2.15x
EV / Sales 2027 * 1.94x
Free-Float
89%
Yield 2026 *
5.6%
Yield 2027 * 5.92%
Current month+4.42%
1 month+5.36%
3 months-7.09%
6 months-2.48%
Current year-6.35%
1 week 11.5
Extreme 11.5
11.9
1 month 11.3
Extreme 11.3
11.9
Current year 10.9
Extreme 10.9
13
1 year 10.9
Extreme 10.9
13.32
3 years 10.9
Extreme 10.9
13.32
5 years 10.9
Extreme 10.9
13.32
10 years 10.9
Extreme 10.9
13.32
Manager TitleAgeSince
Chief Executive Officer 65 2026-04-30
Director of Finance/CFO 64 2024-03-31
Chief Tech/Sci/R&D Officer 51 2023-09-10
Director TitleAgeSince
Director/Board Member 60 2019-04-29
Director/Board Member 57 2020-04-27
Director/Board Member 64 2020-04-27
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 104B
+0.86%+1.43%+47.17%+163.68% 1,067B
+1.59%+4.09%+56.51%+52.50% 635B
+0.95%+1.91%+36.30%+82.78% 458B
+1.60%+6.25%+37.00%+30.00% 347B
-0.60%+1.52%+36.67%+39.80% 295B
-0.14%+0.60%+17.29%+18.19% 262B
+0.09%-2.82%-29.09%-41.29% 216B
+1.22%+2.66%+22.66%+59.87% 203B
-1.18%-3.70%+11.28%+67.52% 161B
Average +0.44%+1.33%+26.20%+52.56% 404.83B
Weighted average by Cap. +0.74%+1.95%+35.99%+78.73%

Financials

2026 *2027 *
Net sales 47.15B 53.7B 43.86B 40.24B 75.66B 5,175B 76.81B 520B 203B 2,540B 201B 197B 8,790B 50.34B 57.33B 46.82B 42.96B 80.77B 5,524B 81.99B 555B 217B 2,711B 215B 211B 9,383B
Net income 8.44B 9.61B 7.85B 7.2B 13.54B 926B 13.74B 93.06B 36.4B 454B 36.05B 35.29B 1,573B 9.44B 10.75B 8.78B 8.05B 15.14B 1,036B 15.37B 104B 40.71B 508B 40.32B 39.47B 1,759B
Net Debt 9.8B 11.16B 9.12B 8.37B 15.73B 1,076B 15.97B 108B 42.3B 528B 41.89B 41B 1,827B 6.15B 7B 5.72B 5.24B 9.86B 674B 10.01B 67.78B 26.51B 331B 26.26B 25.7B 1,145B
Logo Sanofi
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (81.8%): prescription drugs for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases; - human vaccines (18.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2025, the group had 37 production sites worldwide. Net sales are distributed geographically as follows: France (3.9%), Europe (17.1%), the United States (50.8%), China (6%) and other (22.2%).
Employees
74,846
Date Price Change
26-07-24 €11.80 0.00%
26-07-23 €11.80 +0.85%
26-07-22 €11.70 -0.85%
26-07-21 €11.80 0.00%
26-07-20 €11.80 0.00%
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
76.03EUR
Average target price
96.14EUR
Spread / Average Target
+26.45%

Quarterly revenue - Rate of surprise